PT  - JOURNAL ARTICLE
AU  - Lim, Cherry
AU  - Hantrakun, Viriya
AU  - Klaytong, Preeyarach
AU  - Rangsiwutisak, Chalida
AU  - Tangwangvivat, Ratanaporn
AU  - phiancharoen, Chadaporn
AU  - Doung-ngern, Pawinee
AU  - Kripattanapong, Somkid
AU  - Hinjoy, Soawapak
AU  - Yingyong, Thitipong
AU  - Rojanawiwat, Archawin
AU  - Unahalekhaka, Aekkawat
AU  - Kamjumphol, Watcharaporn
AU  - Khobanan, Kulsumpun
AU  - Leethongdee, Phimrata
AU  - Lorchirachoonkul, Narisorn
AU  - Khusuwan, Suwimon
AU  - Siriboon, Suwatthiya
AU  - Chamnan, Parinya
AU  - Vijitleela, Amornrat
AU  - Fongthong, Traithep
AU  - Noiprapai, Krittiya
AU  - Boonyarit, Phairam
AU  - Srisuphan, Voranadda
AU  - Sartorius, Benn
AU  - Stelling, John
AU  - Turner, Paul
AU  - Day, Nicholas PJ
AU  - Limmathurotsakul, Direk
TI  - Higher Frequency and Mortality Rate of Antimicrobial-resistant Bloodstream Infections in Tertiary-care Hospitals Compared with Secondary-care Hospitals in Thailand
AID  - 10.1101/2023.02.07.23285611
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.07.23285611
4099  - http://medrxiv.org/content/early/2023/03/21/2023.02.07.23285611.short
4100  - http://medrxiv.org/content/early/2023/03/21/2023.02.07.23285611.full
AB  - There are few studies comparing proportion, frequency, mortality and mortality rate of antimicrobial-resistant (AMR) bacterial infections between tertiary-care hospitals (TCHs) and secondary-care hospitals (SCHs) in low and middle-income countries (LMICs) to inform infection control strategies. We evaluated bloodstream infections (BSIs) from 2012 to 2015 in 15 TCHs and 34 SCHs in Thailand. There were differences in the proportions (%) of BSI caused by AMR strains for some pathogens between TCHs and SCHs. Of 19,665 patients with AMR BSI, 6,746 (34.3%) died. Among patients with AMR BSI, there were no or minimal differences in mortality proportion for all AMR pathogens between TCHs and SCHs. However, the frequency and mortality rates of AMR BSI were considerably higher in TCHs for most pathogens. For example, the mortality rate of hospital-origin carbapenem-resistant Acinetobacter baumannii BSI in TCHs was nearly three times higher than that in SCHs (10.2 vs. 3.6 per 100,000 patient-days at risk, mortality rate ratio 2.77; 95% confidence interval 1.71 to 4.48, p<0.0001). Targets of and resources for antimicrobial stewardship and infection control programs in LMICs may need to be tailored based on hospital type and size, as burden of AMR infections could differ by hospital setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the DDC, MoPH, Thailand, and Defense Threat Reduction Agency (DTRA), U.S.. This research was funded in part by the Wellcome Trust [224681/Z/21/Z and Wellcome Trust Institutional Translational Partnership Award-MORU]. BS is supported by a grant from the UK Department of Health and Social Care using UK aid funding managed by the Fleming Fund (R52354 CN001). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: https://figshare.com/s/c028f157c18a3cc06a82. Ethical permission for this study was obtained from the Institute for the Development of Human Research Protection, Ministry of Public Health (IHRP 2334/2556), the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University (MUTM 2014-017-01), and the Oxford Tropical Research Ethics Committee, University of Oxford (OXTREC 521-13). Written approval was given by the directors of the hospitals to use their routine hospital admission database for research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript https://figshare.com/s/c028f157c18a3cc06a82